Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.77 |
| ▸ | MAPT | P10636 | 7/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.77 |
| ▸ | HPGD | P15428 | 5/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.77 |
| ▸ | BCHE | P06276 | 5/20 | 0.77 |
| ▸ | ACHE | P22303 | 5/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.77 |
| ▸ | TSHR | P16473 | 4/20 | 0.77 |
| ▸ | TP53 | P04637 | 3/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.77 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.77 |
| ▸ | NPC1 | O15118 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fagaridine SCHEMBL29369428 | 1.00 | ALDH1A1 (0.77) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Fagaridine SCHEMBL8711761 | 0.99 | ALDH1A1 (0.76) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Fagaridine SCHEMBL6961260 | 0.99 | ALDH1A1 (0.78) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Fagaridine SCHEMBL9547964 | 0.99 | ALDH1A1 (0.76) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Fagaridine SCHEMBL8310818 | 0.94 | ALDH1A1 (0.69) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Fagaridine SCHEMBL8310820 | 0.94 | ALDH1A1 (0.69) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Fagaridine SCHEMBL6402891 | 0.93 | ALDH1A1 (0.68) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Fagaridine SCHEMBL31756471 | 0.91 | ALDH1A1 (0.65) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL288915 | 0.87 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL30527168 | 0.87 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1975 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045112-A1 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | TEXAS TECH UNIVERSITY SYSTEM | 2023-02-09 | — | — | US | claimed |
| EP-2805945-B1 | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | MSD ITALIA SRL (IT) | 2019-04-03 | — | — | EP | claimed |
| EP-2603222-B1 | COMBINATORY CANCER TREATMENT | UNIV MONTREAL (CA) | 2018-10-17 | — | — | EP | claimed |
| US-20160346231-A1 | Disulfiram Compositions and Treatments for Brain Tumors | TEXAS TECH UNIVERSITY SYSTEM | 2016-12-01 | — | — | US | claimed |
| WO-2015120254-A1 | DISULFIRAM COMPOSITIONS AND TREATMENTS FOR BRAIN TUMORS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2015-08-13 | — | — | WO | claimed |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. | 2014-10-09 | — | — | US | claimed |
| US-8779171-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2013-06-06 | — | — | US | claimed |
| EP-0487930-B1 | Benzo[C]phenanthridinium derivatives | NIPPON KAYAKU KK (JP) | 1999-03-24 | — | — | EP | claimed |
| EP-0432630-B1 | Antitumor agent | NIPPON KAYAKU KK (JP) | 1994-03-16 | — | — | EP | claimed |
| EP-0432630-A2 | Antitumor agent | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1991-06-19 | — | — | EP | claimed |
| JP-7258218-A | — | — | None | — | — | JP | disclosed |
| US-20260132164-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4076459-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12595248-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| EP-0487930-B1 | Benzo[C]phenanthridinium derivatives | NIPPON KAYAKU KK (JP) | 1999-03-24 | — | — | EP | disclosed |
| JP-H07258218-A | PRODUCTION OF BENZO(C)-PHENANTHRIDINIUM DERIVATIVE | NIPPON KAYAKU CO LTD | 1995-10-09 | — | — | JP | disclosed |
| EP-0432630-B1 | Antitumor agent | NIPPON KAYAKU KK (JP) | 1994-03-16 | — | — | EP | disclosed |
| EP-0487930-A1 | Process for preparing benzo[C]phenanthridinium derivatives, and novel compounds prepared by said process | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1992-06-03 | — | — | EP | disclosed |
| EP-0432630-A2 | Antitumor agent | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045112-A1 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | MGMT, SHMT2, SHMT1 | ALDH1A1 386/4885MAPT 1824/4885SMN1; SMN2 2065/4885 |
| US-12595248-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | ALDH1A1 2476/4885MAPT 4777/4885SMN1; SMN2 118/4885 |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | ALDH1A1 871/4885MAPT 4192/4885SMN1; SMN2 4315/4885 |
| US-20160346231-A1 | Disulfiram Compositions and Treatments for Brain Tumors | MGMT, NNMT, GNMT | ALDH1A1 93/4885MAPT 1150/4885SMN1; SMN2 1407/4885 |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | ALDH1A1 871/4885MAPT 4192/4885SMN1; SMN2 4315/4885 |
| US-20260132164-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | TOP1, NCL, NOLC1 | ALDH1A1 1005/4885MAPT 4774/4885SMN1; SMN2 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.